Prothena Corporation plc
Nov 13, 2012

Prothena to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

South San Francisco, CA, November 13, 2012 – Prothena Corporation, a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that the company’s management team will present a company overview at the Lazard Capital Markets 9th Annual Healthcare Conference on Wednesday, November 14, 2012 at 2:00 p.m. Eastern Time at the Pierre Hotel in New York, NY.

About Prothena Corporation

Prothena Corporation is a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion. Prothena focuses on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease causing proteins. These potential therapies have a broad range of indications including AL and AA forms of amyloidosis, Parkinson’s disease and related synucleinopathies, and novel cell adhesion targets involved in autoimmune disease and metastatic cancers. Prothena’s strategy is to apply our extensive expertise in generating novel therapeutic antibodies and work with collaborators having expertise in specific animal models of disease, to identify antibody candidates for clinical development. For more information, please visit www.neotopebio.com.

Contact:
Paul Cox, Stern Investor Relations, Inc.
212.362.1200, paul@sternir.com